|
시장보고서
상품코드
2050744
휴미라 바이오시밀러 시장 : 제품 유형별, 적응증별, 판매 채널별, 환자 연령별, 지역별Humira Biosimilar Market, By Product Type, By Indication, By Distribution Channel, By Patient Age, By Geography |
||||||
휴미라 바이오시밀러 시장은 2026년에 19억 4,260만 달러로 추정되고 있으며, 2033년까지 98억 4,880만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 26.1%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 19억 4,260만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 26.10% | 2033년 시장 규모 예측 : | 98억 4,880만 달러 |
휴미라는 건선, 류마티스 관절염 등 자가면역질환 치료에 사용되는 생물제제로, 세계에서 가장 널리 보급된 생물제제입니다. 일부 지역에서 휴미라의 특허 보호가 만료됨에 따라 바이오시밀러가 등장했습니다. 바이오시밀러는 안전성, 유효성, 품질 면에서 생물제제와 매우 유사한 복제 의약품입니다. 이러한 바이오시밀러는 경쟁을 촉진하고 가격 하락으로 이어질 수 있습니다. 보다 경제적인 치료 옵션을 제공함으로써 비용 절감과 환자들의 필수 의약품에 대한 접근성 향상에 기여하고 있습니다. 바이오시밀러는 오리지널 생물제제와 동등한 효능과 안전성이 입증되어 건선, 류마티스 관절염 등의 질환을 앓고 있는 환자들에게 효과적인 대안이 되고 있습니다. 또한 바이오시밀러의 보급은 제약업계의 혁신을 촉진하여 제조업체가 품질 저하 없이 보다 저렴한 치료 옵션을 개발하도록 장려합니다. 이러한 시장에서의 경쟁은 가격 인하와 환자 접근성 향상으로 이어져 궁극적으로 의료 결과의 개선으로 이어집니다. 또한 바이오시밀러의 도입은 환자의 선택권과 자율성을 높여 환자가 자신의 특정 요구에 가장 적합한 비용 효율적인 치료법을 선택할 수 있도록 돕습니다.
시장 역학
특허 만료, 비용 절감, 자가면역질환 유병률 증가, 우호적인 규제 환경은 예측 기간 중 글로벌 휴미라 바이오시밀러 시장의 성장을 촉진할 것으로 예상되는 주요 요인으로 꼽힙니다.
예를 들어 여러 휴미라 바이오시밀러가 북미 지역에서 승인 및 출시되어 북미 지역은 바이오시밀러 도입에 있으며, 선구자적인 역할을 하고 있습니다. 이 지역에는 바이오시밀러 도입을 지원하는 기존 법적 프레임워크와 정책이 존재하므로 시장 경쟁이 더욱 치열해져 비용 절감 가능성이 높아질 것으로 예상됩니다.
그러나 복잡한 규제 프로세스, 지적재산권 및 특허 관련 소송, 의사 및 환자 인식 부족 등이 예측 기간 중 글로벌 뇌혈관조영술 시장의 성장을 저해할 것으로 예상됩니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개 변수(회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략)를 기반으로 세계의 휴미라 바이오시밀러 시장의 주요 업체를 분석합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계의 휴미라 바이오시밀러 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 휴미라 바이오시밀러 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 휴미라 바이오시밀러 시장 : 제품 유형별, 2021-2033년
제5장 세계의 휴미라 바이오시밀러 시장 : 적응증별, 2021-2033년
제6장 세계의 휴미라 바이오시밀러 시장 : 환자 연령별, 2021-2033년
제7장 세계의 휴미라 바이오시밀러 시장 : 유통 채널별, 2021-2033년
제8장 세계의 휴미라 바이오시밀러 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSA 26.06.10Humira Biosimilar Market is estimated to be valued at USD 1,942.6 Mn in 2026 and is expected to reach USD 9,848.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 26.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,942.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 26.10% | 2033 Value Projection: | USD 9,848.8 Mn |
Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.
Market Dynamics
Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.
For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.
However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market.
Market Segmentation
- By Product Type (Revenue, USD Mn, 2021 - 2033)
- Biosimilar Humira (Adalimumab)
- Interchangeable Biosimilar Humira
- By Indication (Revenue, USD Mn, 2021 - 2033)
- Rheumatoid Arthritis
- Psoriasis
- Crohn's Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Other Autoimmune Conditions
- By Patient Age (Revenue, USD Mn, 2021 - 2033)
- Adult Patients
- Pediatric Patients
- Geriatric Patients
- By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top companies in Global Humira Biosimilar Market
- Amgen
- Samsung Bioepis Co., Ltd.
- Sandoz International GmbH (Novartis AG)
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences, Inc.
- Biogen Inc.
- AbbVie Inc.
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Viatris Inc.
- Alvotech
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Patient Age
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Patent expiration
- Cost savings
- Increasing prevalence of autoimmune diseases
- Favorable regulatory environment
- Market Restraints
- Market Opportunity
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers Acquisitions, and Collaborations
4. Global Humira Biosimilar Market, By Product Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Biosimilar Humira (Adalimumab)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Interchangeable Biosimilar Humira
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Humira Biosimilar Market, By Indication, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Juvenile Idiopathic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Other Autoimmune Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Humira Biosimilar Market, By Patient Age, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
7. Global Humira Biosimilar Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
8. Global Humira Biosimilar Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/ Region, 2021 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Samsung Bioepis Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sandoz International GmbH (Novartis AG)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Coherus BioSciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Celltrion Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Rani Therapeutics Holdings, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alvotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analysts' Views
- Amgen Inc.
10. Section
- References
- Research Methodology
- About us
